Pages that link to "Q47248499"
Jump to navigation
Jump to search
The following pages link to Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group (Q47248499):
Displaying 50 items.
- Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer (Q24193871) (← links)
- Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism (Q24201186) (← links)
- Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer (Q24234155) (← links)
- Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer (Q24235193) (← links)
- Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism (Q24235236) (← links)
- Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer (Q24236443) (← links)
- Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer (Q24242243) (← links)
- Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism (Q24245782) (← links)
- Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism (Q24246284) (← links)
- Low-molecular-weight heparins in the treatment of venous thromboembolism (Q24792692) (← links)
- Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar (Q24795717) (← links)
- Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism (Q28079081) (← links)
- Pulmonary embolism in hospital practice (Q30476617) (← links)
- Emergency department management of pulmonary embolism (Q33147159) (← links)
- Pharmacology of low molecular weight heparins (Q33340342) (← links)
- Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease (Q33361388) (← links)
- Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach (Q33372266) (← links)
- Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review (Q33380863) (← links)
- Heparin‐associated thrombocytopenia in 24 401 patients with venous thromboembolism: findings from the RIETE Registry (Q33395797) (← links)
- Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction (Q33904621) (← links)
- Acute pulmonary embolism 2: treatment (Q34141332) (← links)
- Direct and indirect antithrombins. Heparins, low molecular weight heparins, heparinoids, and hirudin (Q34196142) (← links)
- Treatment of deep venous thrombosis and pulmonary embolism with low molecular weight heparin in the geriatric patient population (Q34196169) (← links)
- New developments in the prevention and treatment of venous thromboembolism (Q34278849) (← links)
- Low-molecular-weight heparins are essentially the same for treatment and prevention of venous thromboembolism (Q34278853) (← links)
- Unsolved issues in the treatment of pulmonary embolism (Q34376903) (← links)
- Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism (Q34550908) (← links)
- Therapeutic equivalency of low-molecular-weight heparins (Q34648639) (← links)
- Once versus twice daily LMWH for the initial treatment of venous thromboembolism (Q35048657) (← links)
- British Thoracic Society guidelines for the management of suspected acute pulmonary embolism (Q35535961) (← links)
- Tinzaparin: considerations for use in clinical practice (Q35591002) (← links)
- Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation (Q35827649) (← links)
- Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors (Q35866092) (← links)
- Bleeding profiles of anticoagulants, including the novel oral direct thrombin inhibitor ximelagatran: definitions, incidence and management (Q35878355) (← links)
- ASGE guideline: the management of low-molecular-weight heparin and nonaspirin antiplatelet agents for endoscopic procedures (Q36053595) (← links)
- Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety. (Q36128828) (← links)
- Rivaroxaban for the treatment of pulmonary embolism (Q36997736) (← links)
- Recent advances in cardiorespiratory medicine: management of pulmonary embolism and prevention of venous thromboembolism, recent treatment strategies in childhood asthma, and dermatological adverse reactions to cardiovascular drugs (Q37099148) (← links)
- Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings (Q37490581) (← links)
- Prevention and treatment of thromboembolic events in medical patients and new anticoagulants (Q37681486) (← links)
- Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis (Q37766851) (← links)
- Pulmonary thromboembolic disease. Clinical management of acute and chronic disease. (Q37770632) (← links)
- Low molecular weight heparin-induced pharmacological modulation of burn wound healing (Q38638686) (← links)
- Therapeutic monitoring of unfractionated heparin - trials and tribulations (Q38669011) (← links)
- Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin (Q39788611) (← links)
- Complexation of a poly-L-arginine with low molecular weight heparin enhances pulmonary absorption of the drug (Q40063659) (← links)
- Pulmonary delivery of low molecular weight heparins. (Q40482970) (← links)
- Successful thrombolysis following enoxaparin therapy in two pediatric patients with congenital heart disease presenting with intracardiac and cerebral thrombosis (Q42085080) (← links)
- Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers (Q43542034) (← links)
- Outpatient management of DVT using low molecular weight heparin and a hospital outreach service (Q44029837) (← links)